Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

720 ARTÍCULOS , VIENDO DEL 571 AL 585

An interim exploratory proteomics biomarker analysis of a phase 2 clinical trial to assess the impact of CT1812 in Alzheimer's disease

Lizama BN, North HA, Pandey K, Williams C, Duong D, Cho E, Di Caro V, Ping L, Blennow K, Zetterberg H, Lah J, Levey AI, Grundman M, Caggiano AO, Seyfried NT, Hamby ME.

Neurobiol Dis. 2024 Sep;199:106575. doi: 10.1016/j.nbd.2024.106575. Epub 2024 Jun 22.

Alzheimer's disease approaches - Focusing on pathology, biomarkers and clinical trial candidates

Hroudová J, Fišar Z.

Prog Neuropsychopharmacol Biol Psychiatry. 2024 Aug 30;134:111069. doi: 10.1016/j.pnpbp.2024.111069. Epub 2024 Jun 23.

A multicenter, randomized, double-blind, placebo-controlled ascending dose study to evaluate the safety, tolerability, pharmacokinetics (PK) and pharmacodynamic (PD) effects of Posiphen in subjects with early Alzheimer's Disease

Galasko D, Farlow MR, Lucey BP, Honig LS, Elbert D, Bateman R, Momper J, Thomas RG, Rissman RA, Pa J, Aslanyan V, Balasubramanian A, West T, Maccecchini M, Feldman HH.

Alzheimers Res Ther. 2024 Jul 5;16(1):151. doi: 10.1186/s13195-024-01490-z.

Novel Blood-Based Biomarkers and Disease Modifying Therapies for Alzheimer's Disease. Are We Ready for the New Era?

Korologou-Linden R, Kalsi J, Kafetsouli D, Olawale A, Iwata A, Wingfield D, Mummery D, Hayhoe B, Robinson O, Majeed A, Middleton LT.

J Prev Alzheimers Dis. 2024;11(4):897-902. doi: 10.14283/jpad.2024.83.

A phase 2, open-label study of anti-inflammatory NE3107 in patients with dementias

Haroon J, Jordan K, Mahdavi K, Rindner E, Becerra S, Surya JR, Zielinski M, Venkatraman V, Goodenowe D, Hofmeister K, Zhang J, Ahlem C, Reading C, Palumbo J, Pourat B, Kuhn T, Jordan S.

Medicine (Baltimore). 2024 Jul 26;103(30):e39027. doi: 10.1097/MD.0000000000039027.

Blood Biomarkers to Detect Alzheimer Disease in Primary Care and Secondary Care

Palmqvist S, Tideman P, Mattsson-Carlgren N, Schindler SE, Smith R, Ossenkoppele R, Calling S, West T, Monane M, Verghese PB, Braunstein JB, Blennow K, Janelidze S, Stomrud E, Salvadó G, Hansson O.

JAMA. 2024 Oct 15;332(15):1245-1257. doi: 10.1001/jama.2024.13855.

A genetic and proteomic comparison of key AD biomarkers across tissues

Marsh TW, Western D, Timsina J, Gorijala P, Yang C, Pastor P, Liu M, Morris JC, Bateman RJ, Schindler SE, Sung YJ; Dominantly Inherited Alzheimer Network; Cruchaga C.

Alzheimers Dement. 2024 Sep;20(9):6423-6440. doi: 10.1002/alz.14139. Epub 2024 Jul 30.

Tracking neuroinflammatory biomarkers in Alzheimer's disease: a strategy for individualized therapeutic approaches?

Lista S, Imbimbo BP, Grasso M, Fidilio A, Emanuele E, Minoretti P, López-Ortiz S, Martín-Hernández J, Gabelle A, Caruso G, Malaguti M, Melchiorri D, Santos-Lozano A, Imbimbo C, Heneka MT, Caraci F.

J Neuroinflammation. 2024 Jul 30;21(1):187. doi: 10.1186/s12974-024-03163-y.

Association between treatment with sacubitril/valsartan and the risk of Alzheimer's disease: a clinical update

Garnier-Crussard A.

Alzheimers Res Ther. 2024 Aug 1;16(1):177. doi: 10.1186/s13195-024-01547-z.

Transcranial blood-brain barrier opening in Alzheimer's disease patients using a portable focused ultrasound system with real-time 2-D cavitation mapping

Bae S, Liu K, Pouliopoulos AN, Ji R, Jiménez-Gambín S, Yousefian O, Kline-Schoder AR, Batts AJ, Tsitsos FN, Kokossis D, Mintz A, Honig LS, Konofagou EE.

Theranostics. 2024 Jul 22;14(11):4519-4535. doi: 10.7150/thno.94206. eCollection 2024.

The informatics of ADNI

Toga AW, Neu S, Sheehan ST, Crawford K; Alzheimer's Disease Neuroimaging Initiative.

Alzheimers Dement. 2024 Oct;20(10):7320-7330. doi: 10.1002/alz.14099. Epub 2024 Aug 14.

Contributions of the ADNI Biostatistics Core

Beckett LA, Saito N, Donohue MC, Harvey DJ; Alzheimer's Disease Neuroimaging Initiative.

Alzheimers Dement. 2024 Oct;20(10):7331-7339. doi: 10.1002/alz.14159. Epub 2024 Aug 14.

CT1812 biomarker signature from a meta-analysis of CSF proteomic findings from two Phase 2 clinical trials in Alzheimer's disease

Lizama BN, Williams C, North HA, Pandey K, Duong D, Di Caro V, Mecca AP, Blennow K, Zetterberg H, Levey AI, Grundman M, van Dyck CH, Caggiano AO, Seyfried NT, Hamby ME.

Alzheimers Dement. 2024 Oct;20(10):6860-6880. doi: 10.1002/alz.14152. Epub 2024 Aug 21.

Updates in Alzheimer's disease: from basic research to diagnosis and therapies

Liu E, Zhang Y, Wang JZ.

Transl Neurodegener. 2024 Sep 4;13(1):45. doi: 10.1186/s40035-024-00432-x.

Breaking Barriers in Alzheimer's Disease: the Role of Advanced Drug Delivery Systems

Shekho D, Mishra R, Kamal R, Bhatia R, Awasthi A.

AAPS PharmSciTech. 2024 Sep 5;25(7):207. doi: 10.1208/s12249-024-02923-6.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias